Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zeprumetostat in Combination Therapy for Relapsed or Refractory Mature T-cell and NK-cell Lymphomas
NCT07339527Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of zeprumetostat in mature T-cell lymphoma (PTCL), natural killer cell lymphoma (NKCL), sponsored by Sun Yat-sen University. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
zeprumetostat
03
Conditions
mature T-cell lymphoma (PTCL)natural killer cell lymphoma (NKCL)
Beyond the preview
Go deeper on NCT07339527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07339527.